Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

(2020) Amy J. Petty et al.   Cancers

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

(2020) Alba Rodriguez-Garcia et al.   Frontiers in Immunology

LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer

(2020) Ziming Hu et al.   Molecular Therapy-Oncolytics

Improved survival of chimeric antigen receptor‐engineered T ( CAR ‐T) and tumor‐specific T cells caused by anti‐programmed cell death protein 1 single‐chain variable fragment‐producing CAR ‐T cells

(2019) Masao Nakajima et al.   CANCER SCIENCE

The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors

(2019) Changwen Deng et al.   MOLECULAR THERAPY

Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies

(2019) Jiali Cheng et al.   Frontiers in Oncology

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

(2018) Christopher C. Kloss et al.   MOLECULAR THERAPY

IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor

(2018) Keishi Adachi et al.   NATURE BIOTECHNOLOGY

A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects

(2018) Yuki Kagoya et al.   NATURE MEDICINE

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

The Generation and Application of Patient-Derived Xenograft Model for Cancer Research

(2018) Jaeyun Jung et al.   Cancer Research and Treatment

Tumor Antigen Escape from CAR T-cell Therapy

(2018) Robbie G. Majzner et al.   Cancer Discovery

Emerging Cellular Therapies for Cancer

(2018) Sonia Guedan et al.   Annual Review of Immunology

CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions

(2018) Wanghong Hu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells

(2018) Ruocong Zhao et al.   OncoImmunology

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells

(2017) Thomas Shum et al.   Cancer Discovery

Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells

(2017) Hua Jiang et al.   Protein & Cell

Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma

(2017) Zhiwu Jiang et al.   Frontiers in Immunology

PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells

(2017) Xinru Wei et al.   OncoImmunology

Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies

(2016) Marco Ruella et al.   Computational and Structural Biotechnology Journal

Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

(2015) C. E. Brown et al.   CLINICAL CANCER RESEARCH

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumorsin vivo

(2015) Mythili Koneru et al.   OncoImmunology

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment

(2013) Thomas F Gajewski et al.   CURRENT OPINION IN IMMUNOLOGY

Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies

(2012) K. Tamada et al.   CLINICAL CANCER RESEARCH

Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor

(2011) Evripidis Lanitis et al.   MOLECULAR THERAPY

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY